Research programme: glycoprotein based therapeutics - GlycoForm

Drug Profile

Research programme: glycoprotein based therapeutics - GlycoForm

Alternative Names: GLY 510; GLY 511; GLY 515n

Latest Information Update: 27 Jun 2012

Price : $50

At a glance

  • Originator GlycoForm
  • Developer Aston University; Cerebricon; GlycoForm (CEASED); PolyTherics
  • Class Glycoproteins; Peptide fragments
  • Mechanism of Action Erythropoiesis stimulants; Glycosylation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anaemia; Gaucher's disease; Stroke

Most Recent Events

  • 31 Dec 2011 Discontinued - Preclinical for Stroke in Finland (IV)
  • 31 Dec 2011 Discontinued for Gaucher's disease in United Kingdom (Parenteral)
  • 31 Dec 2011 Discontinued for Anaemia in United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top